SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q4 2025 vs. Q3 2025
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 10 | 7 | −3 |
| Shares | 829.5K | 275.5K | −554.0K (−66.8%) |
| Value | $19.5K | $8.34K | −$11.2K (−57.3%) |
New holders (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| GTS Securities LLC | 41,101 | $1.03K | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| LMR Partners LLP | 539,588 | $12.6K |
| Susquehanna International Group, LLP | 26,302 | $750 |
| Walleye Trading LLC | 11,436 | $268 |
| Toronto Dominion Bank | 200 | $5 |